1. Introduction
Ensuring an appropriate level and duration of expression is essential in achieving an efficient and safe gene therapy. While the length of time a gene must be expressed for efficacy depends on both the therapeutic strategy and the disease, many gene therapy approaches prove ineffective as the therapeutic is expressed for a limited duration (Frank et al. 2004). Proposed causes of transient expression include loss of DNA due to cell turnover, immune responses against transfected cells and/or expressed proteins, and inhibition of transcription through host cell methylation of microbial DNA sequences (Prosch et al. 1996; Scheule 2000; Greenland et al. 2007). Vector related elements or activity also contribute to duration of gene expression post administration. Adenovirus is known to stimulate severe innate and adaptive immune responses, and can induce cellular and humoural responses to the transgene product and its capsid proteins resulting in failure to provide long-term gene expression (Jooss et al. 1998; Yuasa et al. 2002; Louboutin et al. 2005; Wang et al. 2005).
Plasmid electroporation, on the other hand, has been shown not to elicit such transgene gene silencing immune responses (Jooss et al. 1998; Mir et al. 1999), and presents an attractive option in achieving long-term gene expression, especially in light of recent improvements in plasmid vectors (Gill et al. 2009). Although plasmid based systems offer certain advantages, they do, however, have drawbacks. The magnitude of transgene expression is generally lower with plasmid vectors than that with viruses. In addition, most plasmids are not passed on to daughter cells following cell division leading to eventual loss of expression in rapidly dividing tissues. This can result in sub-therapeutic effects, a significant problem with gene therapy. Efforts have been made to ensure that therapeutic protein production is active for an appropriate length of time to address some of these failings. To counteract the effects of episomal DNA loss, the use of integrating DNA in the form of retroviruses or transposon containing plasmids has been examined and shown some efficacy(Sandrin et al. 2003; Ohlfest et al. 2005). Delivery in this fashion would lead to long lasting, possibly indefinite gene expression. Although this addresses one failing of plasmid delivery, the potential of indefinite and uncontrollable protein production to cause unexpected side effects is an issue. Unlike the current situation, where therapy related complications results in withdrawal of the medication, the “offending gene” cannot easily be removed, and may continue to cause significant side effects. In addition, integration of foreign DNA is not ideal as it can lead to mutagenesis, with subsequent alteration in the patient’s protein expression profile and potentially carcinogenesis. With this in mind, methods of prolonging and/or controlling episomal gene expression are preferred, provided this expression is of sufficient magnitude.
Plasmid loss alone may not fully account for the temporal loss of expression seen with these vectors. Epigenetic modification of the therapeutic has also been implicated in gene silencing, but the exact mechanisms by which this occurs have not yet been fully elucidated. It has been demonstrated that duration of transgene expression may by increased by use of ‘native’ promoters of mammalian origin rather than viral promoters (Gazdhar et al. 2006). The postulated mechanism behind this difference of expression relates to the presence and subsequent methylation of CpG sequences on promoters. This methylation is a naturally occurring phenomenon and reports have correlated methylation of CpG-rich sequences with silencing of gene expression (Gazdhar, Bilici et al. 2006). Native mammalian promoters possess fewer CpG sequences than their viral counterparts and are theoretically less prone to silencing. By employing mammalian promoters, the duration of gene expression may be extended, allowing for sustained therapeutic production. Anecdotal evidence suggests that the degree of viral promoter silencing varies between tissue types, and that the duration of gene expression in tumour tissue in particular may be short-lived (Jaenisch et al. 1985; Momparler & Bovenzi 2000; Bartoli et al. 2003). This may, in part, be due to abnormal cell turnover in tumour tissue, but the disorganised methylation pattern in tumour tissue could also play a role.
In this chapter, we assess the influence of promoter type on electroporated plasmid transgene expression in murine models. Expression is examined by utilising the reporter gene luciferase. The activity of luciferase can then be measured
2. Materials and methods
2.1. DNA constructs
pGL3-Control and pCMV-luc were purchased from Stratagene (Techno-Path, Limerick, Ireland) and Promega (Medical Supply Co., Dublin, Ireland) respectively. pDRIVE03-UbiquitinB(h) v02 was purchased from Invivogen (Cayla SAS, Toulouse, France). A version of this plasmid, designated pUb-luc, containing the firefly
2.2. Animals and tumour induction
Murine JBS fibrosarcoma tumour cells were maintained in culture in Dulbecco’s Modified Essential Medium (DMEM) (GIBCO, Invitrogen Corp., Paisley, Scotland) as previously described (Collins, C. G. et al. 2006; Collins, S. A. et al. 2010). Female Balb/C and MF1nu/nu mice of 6–8 weeks of age were obtained from Harlan Laboratories (Oxfordshire, England). For routine tumour induction, 2 × 106 JBS cells suspended in 200 μl serum free DMEM were injected subcutaneously into the flank.
2.3. In-vivo gene delivery
For tumour experiments, mice were treated at a tumour volume of approximately 100 mm3 in volume (5-7 mm major diameter). Mice were anaesthetized during all treatments by intraperitoneal (i.p.) administration of 200 µg xylazine and 2 mg ketamine. For liver transfection, a 1 cm subcostal incision was made over the liver and the peritoneum opened. The right lobe of the exposed liver was administered plasmid by electroporation as described below (Casey et al. 2010; Collins, S. A. et al. 2011). The wound was closed in two layers, peritoneal and skin, using 4/0 prolene sutures (Promed, Killorglin, Ireland). For plasmid delivery by electroporation, a custom-designed applicator with 2 needles 4 mm apart was used, with both needles placed through the skin central to the tissue. Tissue was injected between electrode needles with 8 x 1011 copies of plasmid DNA in sterile injectable saline in an injection volume of 50 µl. After 80 seconds, square-wave pulses (1200 V/cm 100 µsec x 1 and 120 V/cm 20 msec, 8 pulses) were administered in sequence using a custom designed pulse generator (Cliniporator (IGEA, Carpi, Italy).
2.4. Inhibition of DNA acetylation in vivo
Individual animals were weighed and dosed by i.p. injection of trichostatin A (TSA) (Sigma) at 10 mg/kg in 60 μl 10% (v/v) dimethyl sulfoxide in filtered peanut oil, daily for the duration of the experiment.
2.5. Whole body imaging
2.6. Assessment of plasmid DNA in liver tissue using PCR analysis
To determine the presence of plasmid DNA in liver tissue, pCMV-Luc was delivered to the livers of 9 mice using electroporation as previously described. Luciferase expression was assessed by IVIS imaging at the time of sampling, 24 hr, 3 days and 10 days post treatment. Livers from three mice were excised at each time-point and snap frozen in liquid nitrogen. Livers were homogenized in TRIZOL Reagent (Invitrogen) using an Ultra Turrax T25 homogeniser (IKA Werke GmbH & Co. KG, Staufen, Germany) and total DNA was extracted as per the manufacturer’s protocol. The presence of the plasmid DNA in the total DNA was determined by PCR using
2.7. Statistical analysis
The primary outcome variable of the statistical analyses was luminescence per cell per gene copy administered in each cell line or luminescence per gene copy administered in each organ measured at each time point. The principal explanatory variables were the delivery modalites used.
3. Results
Plasmid DNA encoding the luciferase gene transcribed from either the CMV (pCMV-luc) or Ubiquitin-B (pUb-luc) promoter was delivered to murine liver or quadriceps muscle by
The kinetics of CMV, Ub and SV40 promoter activity were also analysed in tumour bearing mice. pCMV-luc, pUb-luc or pGL3 DNA was electroporated to subcutaneous (s.c.) JBS fibrosarcoma tumours upon reaching 80 mm3 in volume. IVIS imaging over 18 days (the limit of tumour monitoring before animals required culling) demonstrated that the initially high expression driven by the CMV promoter was rapidly reduced to background level by day 4-post transfection (figure 2). Reduction was also observed with SV40 promoter, albeit with a heterologous temporal expression pattern to CMV, with pGL3 expression peaking at day 4 before rapidly reducing to background levels. Ub promoter activity was still evident at the final time point. pCMV-luc and pGL3 displayed statistically similar (p = 0.98) maximum to minimum rates of silencing (2.9 x 10-7 p/sec/cm2/sr/gene copy per day), higher than that of pUb-luc (6.8 x 10-8 p/sec/cm2/sr/gene copy per day). pCMV-luc expression was also found to rapidly reduce in s.c. human MCF7 breast carcinoma tumours growing in athymic mice (data not shown). Ubiquitin-B promoter transcriptional activity may be related to the normal functions of ubiquitin in cells, which is expressed constitutively for removing abnormal proteins and for modification of histones leading to gene activation, and so may not be subject to the down-regulation observed with many viral promoters (Ciechanover et al. 2000; Yew et al. 2001). Ubiquitin is also induced in response to cell stress, and expression might be up-regulated in response to cellular necrosis and apoptosis, which is especially relevant in growing tumours. Given that pUb-luc expression is evident long after viral promoter activity diminishes (up to day 25 for pUb-luc as opposed to day 7 for pCMV-luc and pGL3; figure 2), it is plausible that viral promoter plasmids remain present in liver post cessation of expression.
To test for the presence of plasmid, DNA was extracted from murine livers at various times post transfection with pCMV-luc and PCR analysis performed. DNA PCR results from days 1, 3 and 10 confirmed the presence of
In order to examine any effects of T-cell mediated immune activity on viral promoter construct expression, pCMV-luc expression in livers of athymic mice was examined. No difference in the magnitude or duration of expression was observed between immune competent Balb/C and T-cell deficient mice, suggesting that cellular immune responses were not involved in the observed reduction in hepatic expression of pCMV-luc (figure 4a). Other studies have indicated that luciferase protein has low immunogenicity, and immune-mediated destruction of luciferase-producing cells does not occur in mice (Davis et al. 1997), while the persistence of expression in muscle here also makes this unlikely as a cause for silencing in other tissues. The observation of indefinite expression in plasmid electroporated muscle is in direct contrast to Ad expression in quadriceps muscle, which has been shown to be eliminated through T cell and antibody immune activities and/or CMV promoter methylation (Jooss, Yang et al. 1998; Brooks et al. 2004).
4. Discussion
We did not determine the reasons for the observed tissue-specific nature of viral promoter silencing, and it remains unclear as to why liver and tumour, but not muscle, affected plasmid expression. Plasmids function predominantly in an episomal fashion and copy number per cell is reduced proportional to cell replication. As such, genes would be expected to be diluted rapidly in tissues with a high mitotic index. Liver hepatocytes and skeletal myocytes are fully differentiated and have a low turnover, unlike tumour cells. (Ayers & Jeffery 1988) It may be hypothesised that the static nature of cell turnover in muscle compared with tumour is relevant in this context. However, this cannot fully account for the observed loss of expression, since in our study, the rate of reduction of expression for plasmids with promoters of mammalian and viral origin was different. Also, previous studies have shown no alteration in longevity of transgene expression when cell turnover was inhibited (Herweijer et al. 2001). Furthermore, we demonstrated by PCR that pCMV-luc persisted in liver cells after expression ceased. We think it is unlikely that the reduction in pCMV-luc expression was due to a parallel reduction in the plasmid DNA as this was not seen for the Ub promoter where similar plasmid copy numbers would be expected.
It has previously been demonstrated that plasmid transgene expression can be modulated with chromatin remodelling agents (Bartoli, Fettucciari et al. 2003). To this end, murine livers were electroporated with pCMV-luc and mice systemically administered the histone deacetylase inhibitor trichostatin-A (TSA) daily for the duration of experiment. TSA is a specific inhibitor for histone deacetylase (HDAC) and is known to enhance gene expression in viral and plasmid-transfected cells
While this study did not generate data to correlate RNA levels with luminescence, differences in transcription appears to be the key element in observed expression levels. Firefly luciferase protein is known to have a short half-life
Our findings are consistent with previous studies in lung tissue where the levels and duration of transgene expression
5. Conclusion
In summary these results highlight the importance of promoter,tissue and vector variables in achieving appropriate transgene expression for DNA therapeutic strategies.
Acknowledgment
This work was funded by Cancer Research Ireland (CRI07TAN) and the Cork Cancer Research Centre.
References
- 1.
Al-Dosari M. Zhang G. Knapp J. E. Liu D. 2006 Evaluation of viral and mammalian promoters for driving transgene expression in mouse liver Biochem Biophys Res Commun339 2 673 8 - 2.
Ayers M. M. Jeffery P. K. 1988 Proliferation and differentiation in mammalian airway epithelium. Eur Respir J1 1 58 80 - 3.
Baggett B. Roy R. Momen S. Morgan S. Tisi L. Morse D. Gillies R. J. 2004 Thermostability of firefly luciferases affects efficiency of detection by in vivo bioluminescence Mol Imaging3 4 324 32 - 4.
Bartoli A. Fettucciari K. Fetriconi I. Rosati E. Di Ianni M. Tabilio A. Delfino D. V. Rossi R. Marconi P. 2003 Effect of trichostatin a and 5’-azacytidine on transgene reactivation in U937 transduced cells Pharmacol Res48 1 111 8 - 5.
Brooks A. R. Harkins R. N. Wang P. Qian H. S. Liu P. Rubanyi G. M. 2004 Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med6 4 395 404 - 6.
Casey G. Cashman J. P. Morrissey D. Whelan M. C. Larkin J. O. Soden D. M. Tangney M. O’Sullivan G. C. 2010 Sonoporation mediated immunogene therapy of solid tumors Ultrasound Med Biol 36(3):430 EOF 440 EOF X (Electronic)0301-5629 (Linking) - 7.
Ciechanover A. Orian A. Schwartz A. L. 2000 Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays22 5 442 51 - 8.
Collins C. G. Tangney M. Larkin J. O. Casey G. Whelan M. C. Cashman J. Murphy J. Soden D. Vejda S. Mc Kenna S. Kiely B. Collins J. K. Barrett J. Aarons S. O’Sullivan G. C. 2006 Local gene therapy of solid tumors with GM-CSF and B Cancer Gene Ther7 1 eradicates both treated and distal tumors. - 9.
Collins S. A. Buhles A. Scallan M. F. Harrison P. T. O’Hanlon D. M. O’Sullivan G. C. Tangney M. 2010 AAV Genet Vaccines Ther 8: 81479-0556 (Electronic)1479-0556 (Linking)2 -mediated in vivo immune gene therapy of solid tumours. - 10.
Collins S. A. Morrissey D. Rajendran S. Casey G. Scallan M. F. Harrison P. T. O’Sullivan G. C. Tangney M. 2011 Comparison of DNA Delivery and Expression Using Frequently Used Delivery Methods. Gene Therapy- developments and future perspectives. C. Kang, InTech. - 11.
Davis H. L. Millan C. L. Watkins S. C. 1997 Immune-mediated destruction of transfected muscle fibers after direct gene transfer with antigen-expressing plasmid DNA. Gene Ther4 3 181 8 - 12.
Di Ianni M. Terenzi A. Perruccio K. Ciurnelli R. Lucheroni F. Benedetti R. Martelli M. F. Tabilio A. 1999 Gene Ther 6(4): 703-70969-7128 (Print)5 -Azacytidine prevents transgene methylation in vivo. - 13.
Frank O. Rudolph C. Heberlein C. von Neuhoff. N. Schrock E. Schambach A. Schlegelberger B. Fehse B. Ostertag W. Stocking C. Baum C. 2004 Tumor cells escape suicide gene therapy by genetic and epigenetic instability. 104 12 3543 9 - 14.
Gazdhar A. Bilici M. Pierog J. Ayuni E. L. Gugger M. Wetterwald A. Cecchini M. Schmid R. A. 2006 In vivo electroporation and ubiquitin promoter- a protocol for sustained gene expression in the lung." J Gene Med8 7 910 918 - 15.
Gill D. R. Pringle I. A. Hyde S. C. 2009 Progress and prospects: the design and production of plasmid vectors Gene Ther16 2 165 71 - 16.
Gill D. R. Smyth S. E. Goddard C. A. Pringle I. A. Higgins C. F. Colledge W. H. Hyde S. C. 2001 Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1alpha promoter. Gene Ther8 20 1539 46 - 17.
Greenland J. R. Geiben R. Ghosh S. Pastor W. A. Letvin N. L. 2007 Plasmid DNA vaccine-elicited cellular immune responses limit in vivo vaccine antigen expression through Fas-mediated apoptosis. J Immunol178 9 5652 8 - 18.
Herweijer H. Zhang G. Subbotin V. M. Budker V. Williams P. Wolff J. A. 2001 Time course of gene expression after plasmid DNA gene transfer to the liver. J Gene Med3 3 280 91 - 19.
Jaenisch R. Schnieke A. Harbers K. 1985 Treatment of mice with 5-azacytidine efficiently activates silent retroviral genomes in different tissues Proc Natl Acad Sci U S A82 5 1451 5 - 20.
Jooss K. Ertl H. C. Wilson J. M. 1998 Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J Virol72 4 2945 54 - 21.
Jooss K. Yang Y. Fisher K. J. Wilson J. M. 1998 Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers J Virol72 5 4212 23 - 22.
Kanai Y. 2008 Alterations of DNA methylation and clinicopathological diversity of human cancers Pathol Int58 9 544 58 - 23.
Louboutin J. P. Wang L. Wilson J. M. 2005 Gene transfer into skeletal muscle using novel AAV serotypes. J Gene Med7 4 442 51 - 24.
Mir L. M. Bureau M. F. Gehl J. Rangara R. Rouy D. Caillaud J. M. Delaere P. Branellec D. Schwartz B. Scherman D. 1999 High-efficiency gene transfer into skeletal muscle mediated by electric pulses Proc Natl Acad Sci U S A96 8 4262 7 - 25.
Momparler R. L. Bovenzi V. 2000 DNA methylation and cancer. J Cell Physiol183 2 145 54 - 26.
Morrissey D. van Pijkeren J. P. Rajendran S. Collins S. A. Casey G. O’Sullivan G. C. Tangney M. 2012 Control and augmentation of long-term plasmid transgene expression in vivo in murine muscle tissue and ex vivo in patient mesenchymal tissue J Biomed Biotechnol 2012: 3798451110-7251 (Electronic)1110-7243 (Linking) - 27.
Ohlfest J. R. Demorest Z. L. Motooka Y. Vengco I. Oh S. Chen E. Scappaticci F. A. Saplis R. J. Ekker S. C. Low W. C. Freese A. B. Largaespada D. A. 2005 Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. Mol Ther12 5 778 88 - 28.
Prosch S. Stein J. Staak K. Liebenthal C. Volk H. D. Kruger D. H. 1996 Inactivation of the very strong HCMV immediate early promoter by DNA CpG methylation in vitro. Biol Chem Hoppe Seyler377 3 195 201 - 29.
Sandrin V. Russell S. J. Cosset F. L. 2003 Targeting retroviral and lentiviral vectors." Curr Top Microbiol Immunol281 137 78 - 30.
Scheule R. K. 2000 The role of CpG motifs in immunostimulation and gene therapy. Adv Drug Deliv Rev 44(2-3):119 EOF 34 EOF - 31.
Tang Q. Maul G. G. 2003 Mouse cytomegalovirus immediate-early protein 1 binds with host cell repressors to relieve suppressive effects on viral transcription and replication during lytic infection. J Virol77 2 1357 67 - 32.
Tangney M. Francis K. P. 2012 In vivo optical imaging in gene & cell therapy." Curr Gene Ther 12(1): 2-111875-5631 (Electronic)1566-5232 (Linking) - 33.
Vanniasinkam T. Ertl H. Tang Q. 2006 Trichostatin-A enhances adaptive immune responses to DNA vaccination J Clin Virol36 4 292 7 - 34.
Wang L. Dobrzynski E. Schlachterman A. Cao O. Herzog R. W. 2005 Systemic protein delivery by muscle-gene transfer is limited by a local immune response. 105 11 4226 34 - 35.
Yew N. S. Przybylska M. Ziegler R. J. Liu D. Cheng S. H. 2001 High and sustained transgene expression in vivo from plasmid vectors containing a hybrid ubiquitin promoter Mol Ther4 1 75 82 - 36.
Yuasa K. Sakamoto M. Miyagoe-Suzuki Y. Tanouchi A. Yamamoto H. Li J. Chamberlain J. S. Xiao X. Takeda S. 2002 Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product. Gene Ther9 23 1576 88